01两大引擎驱动盈利乐普生物成立于2018年,是一家专注于靶向治疗和肿瘤免疫治疗的创新型生物制药企业,在七年研发投入的积累下终于开始转化为财务回报。这一突破性进展的核心驱动因素来自两大引擎:PD-1单抗商业化放量:普特利单抗(商品名:普佑恒)虽然是国内获批第14款获批上市的PD-1/PD-L1单抗,但也成功在免疫治疗领域占得一席之地。目前,该药已获批黑色素瘤、MSI-H/dMMR实体瘤两项适应症。...
Source Link01两大引擎驱动盈利乐普生物成立于2018年,是一家专注于靶向治疗和肿瘤免疫治疗的创新型生物制药企业,在七年研发投入的积累下终于开始转化为财务回报。这一突破性进展的核心驱动因素来自两大引擎:PD-1单抗商业化放量:普特利单抗(商品名:普佑恒)虽然是国内获批第14款获批上市的PD-1/PD-L1单抗,但也成功在免疫治疗领域占得一席之地。目前,该药已获批黑色素瘤、MSI-H/dMMR实体瘤两项适应症。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.